{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:34:15Z","timestamp":1790706855833,"version":"4.1.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/sla.0b013e31823d813c","type":"journal-article","created":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T00:18:01Z","timestamp":1322266681000},"page":"95-102","source":"Crossref","is-referenced-by-count":129,"title":["Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer"],"prefix":"10.1097","volume":"255","author":[{"given":"Hidenori","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ohigashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R2-15-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00000658-199603000-00007","article-title":"Long-term survival after curative resection for pancreatic ductal adenocarcinoma: Clinicopathologic analysis of 5-year survivors.","volume":"223","author":"Conlon","year":"1996","journal-title":"Ann Surg"},{"key":"R3-15-20210203","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00000658-199302000-00008","article-title":"Resection margins in carcinoma of the head of the pancreas: Implications for radiation therapy.","volume":"217","author":"Willett","year":"1993","journal-title":"Ann Surg"},{"key":"R5-15-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"R6-15-20210203","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000113054","article-title":"The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis.","volume":"72","author":"Boeck","year":"2007","journal-title":"Oncology"},{"key":"R7-15-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/SLA.0b013e318181e4e9","article-title":"Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study.","volume":"248","author":"Linehan","year":"2008","journal-title":"Ann Surg"},{"key":"R8-15-20210203","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-15-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejso.2007.07.204","article-title":"Neoadjuvant and adjuvant strategies for pancreatic cancer.","volume":"34","author":"Ghaneh","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"R11-15-20210203","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JCO.1997.15.3.928","article-title":"Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.","volume":"15","author":"Spitz","year":"1997","journal-title":"J Clin Oncol"},{"key":"R12-15-20210203","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.2002.11.064","article-title":"Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome.","volume":"20","author":"Pisters","year":"2002","journal-title":"J Clin Oncol"},{"key":"R13-15-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2006.03.039","article-title":"A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.","volume":"13","author":"Talamonti","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R14-15-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10434-001-0123-4","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration.","volume":"8","author":"Breslin","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"R15-15-20210203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/SLA.0b013e3181ad65cc","article-title":"Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.","volume":"250","author":"Ohigashi","year":"2009","journal-title":"Ann Surg"},{"key":"R16-15-20210203","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ejso.2007.11.012","article-title":"Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.","volume":"34","author":"Golcher","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"R17-15-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0b013e318172d5c5","article-title":"Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial.","volume":"31","author":"Le Scodan","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R18-15-20210203","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2004.04.004","article-title":"Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma.","volume":"60","author":"Moutardier","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-15-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1245\/ASO.2005.03.105","article-title":"Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.","volume":"12","author":"White","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R20-15-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1385\/IJGC:34:2-3:121","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Analysis of histopathology and outcome.","volume":"34","author":"Sasson","year":"2003","journal-title":"Int J Gastrointest Cancer"},{"key":"R21-15-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1998.16.1.317","article-title":"Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study.","volume":"16","author":"Hoffman","year":"1998","journal-title":"J Clin Oncol"},{"key":"R22-15-20210203","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ijrobp.2006.02.054","article-title":"Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.","volume":"65","author":"Mornex","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-15-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/07357900701206356","article-title":"Neoadjuvant therapy in pancreatic cancer.","volume":"25","author":"Quiros","year":"2007","journal-title":"Cancer Invest"},{"key":"R24-15-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/SLA.0b013e3181cc90a3","article-title":"Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.","volume":"251","author":"Takahashi","year":"2010","journal-title":"Ann Surg"},{"key":"R25-15-20210203","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","article-title":"Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.","volume":"17","author":"Katz","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R26-15-20210203","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1245\/s10434-008-0295-2","article-title":"Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.","volume":"16","author":"Katz","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R27-15-20210203","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1349-7006.2005.00128.x","article-title":"Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas.","volume":"96","author":"Mitsunaga","year":"2005","journal-title":"Cancer Sci"},{"key":"R28-15-20210203","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1097\/PAS.0b013e318065bfe6","article-title":"Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact.","volume":"31","author":"Mitsunaga","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R29-15-20210203","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation andor chemotherapy in the ESPAC-1 randomized controlled trial.","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"key":"R30-15-20210203","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.surg.2006.12.013","article-title":"Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer.","volume":"141","author":"Pawlik","year":"2007","journal-title":"Surgery"},{"key":"R31-15-20210203","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00268-002-6659-z","article-title":"Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.","volume":"27","author":"Richter","year":"2003","journal-title":"World J Surg"},{"key":"R32-15-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1245\/s10434-007-9587-1","article-title":"Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: A large, population-based analysis.","volume":"15","author":"Slidell","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R33-15-20210203","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators.","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastrointest Surg"},{"key":"R35-15-20210203","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.","volume":"127","author":"Evans","year":"1992","journal-title":"Arch Surg"},{"key":"R36-15-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.2930400303","article-title":"Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region.","volume":"40","author":"Ishikawa","year":"1989","journal-title":"J Surg Oncol"},{"key":"R38-15-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00000658-198808000-00014","article-title":"Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head.","volume":"208","author":"Ishikawa","year":"1988","journal-title":"Ann Surg"},{"key":"R39-15-20210203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0002-9610(05)80167-9","article-title":"Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.","volume":"168","author":"Ishikawa","year":"1994","journal-title":"Am J Surg"},{"key":"R42-15-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00006676-200201000-00003","article-title":"Perineural invasion in pancreatic cancer.","volume":"24","author":"Hirai","year":"2002","journal-title":"Pancreas"},{"key":"R43-15-20210203","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/bjs.1800800526","article-title":"Perineural invasion of carcinoma of the pancreas and biliary tract.","volume":"80","author":"Nagakawa","year":"1993","journal-title":"Br J Surg"},{"key":"R44-15-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1098-2388(199807\/08)15:1<15::AID-SSU4>3.0.CO;2-Z","article-title":"Clinical usefulness of CA-19-9 in pancreatic carcinoma.","volume":"15","author":"Nakao","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"R45-15-20210203","first-page":"1407","article-title":"Extra-tumor perineural invasion predicts postoperative development of peritoneal dissemination in pancreatic ductal adenocarcinoma.","volume":"21","author":"Takahashi","year":"2001","journal-title":"Anticancer Res"},{"key":"R46-15-20210203","first-page":"51","article-title":"Clinicopathological study on neural invasion to the extrapancreatic nerve plexus in pancreatic cancer.","volume":"39","author":"Nagakawa","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"R47-15-20210203","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/mpa.0b013e3180619677","article-title":"The nature of neural invasion by pancreatic cancer.","volume":"35","author":"Kayahara","year":"2007","journal-title":"Pancreas"},{"key":"R48-15-20210203","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"R49-15-20210203","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/onc.2011.59","article-title":"Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity.","volume":"30","author":"Akita","year":"2011","journal-title":"Oncogene"},{"key":"R50-15-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"R51-15-20210203","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-08-2080","article-title":"Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.","volume":"15","author":"Marechal","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R52-15-20210203","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.gastro.2009.10.050","article-title":"Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis.","volume":"138","author":"Bishnupuri","year":"2010","journal-title":"Gastroenterology"},{"key":"R53-15-20210203","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/MPA.0b013e3181ac5337","article-title":"Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer.","volume":"38","author":"Eguchi","year":"2009","journal-title":"Pancreas"},{"key":"R54-15-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s005340200000","article-title":"Molecular prognostic markers in pancreatic cancer.","volume":"9","author":"Ghaneh","year":"2002","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R55-15-20210203","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1078-0432.CCR-09-1555","article-title":"Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.","volume":"16","author":"Okazaki","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R56-15-20210203","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.10754","article-title":"On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.","volume":"95","author":"McGinn","year":"2002","journal-title":"Cancer"},{"key":"R57-15-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0360-3016(03)00435-8","article-title":"Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study.","volume":"57","author":"Li","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R58-15-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0360-3016(03)00449-8","article-title":"Radiation therapy with once-weekly gemcitabine in pancreatic cancer: Current status of clinical trials.","volume":"56","author":"McGinn","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R59-15-20210203","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2007.13.9014","article-title":"Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial.","volume":"26","author":"Small","year":"2008","journal-title":"J Clin Oncol"},{"key":"R60-15-20210203","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(95)02134-5","article-title":"Radiosensitization of pancreatic cancer cells by 2,2-difluoro-2-deoxycytidine.","volume":"34","author":"Lawrence","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R61-15-20210203","first-page":"777","article-title":"Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2,2-difluoro-2-deoxycytidine (Gemcitabine).","volume":"3","author":"Lawrence","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R62-15-20210203","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0360-3016(99)00134-0","article-title":"Maximizing therapeutic gain with gemcitabine and fractionated radiation.","volume":"44","author":"Mason","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R63-15-20210203","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000658-201201000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:41Z","timestamp":1786047881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000658-201201000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0b013e31823d813c","relation":{},"ISSN":["0003-4932"],"issn-type":[{"value":"0003-4932","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}